Myfenax

Manufactured by Teva Pharmaceuticals

Myfenax is a laboratory equipment product designed for use in pharmaceutical research and development. It serves as a tool for the controlled synthesis and purification of chemical compounds. The core function of Myfenax is to facilitate the efficient and reproducible preparation of pharmaceutical ingredients.

Automatically generated - may contain errors

Lab products found in correlation

Prograf, by Astellas Pharma (1 mentions) Thymoglobulin, by Sanofi (1 mentions) Zenapax, by Roche (1 mentions) Neoral, by Novartis (1 mentions) Simulect, by Novartis (1 mentions)

2 protocols using myfenax

Immunosuppressive Therapy Monitoring in Transplant Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients received the same immunosuppressive therapy according to the clinical protocol of the IMAGEN study [4 (link)] and in line with the local standard of care. Immunosuppressive treatment consisted of tacrolimus (Prograf^®, Astellas Pharma), mycophenolate mofetil (Myfenax^®, Teva Pharmaceuticals), and methylprednisolone. All patients received an induction treatment of two 20-mg doses of basiliximab. From each patient, blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours after drug administration in the 1^st week and at 0, 1.5, 2 and 4 hours after drug administration in the 1^st, 2^nd, 3^rd and 6^th months after transplantation. Drug analysis was performed in the respective centers involved in the study. Tacrolimus concentrations were measured in whole blood by liquid chromatography/tandem mass spectrometry, whereas MPA concentrations were determined in plasma by high-performance liquid chromatography with ultraviolet detection [15 (link)–17 (link)].

Quintairos L., Colom H., Millán O., Fortuna V., Espinosa C., Guirado L., Budde K., Sommerer C., Lizana A., López-Púa Y, & Brunet M. (2021). Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. PLoS ONE, 16(1), e0245880.

+ Open protocol

+ Expand

Induction and Maintenance Immunosuppression Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

As induction, patients received intravenous rATG (Thymoglobulin; Genzyme, Cambridge, MA) 4 mg/kg total dose from days 0 to 3 and intravenous methylprednisolone 500 mg on day 0 and 250 mg on days 1 and 2. Recipients with a history of malignancy or hematologic disorder received intravenous basiliximab (Simulect; Novartis, Basel, CH) 20 mg on days 0 and 4 or daclizumab (Zenapax; Roche, Basel, CH) 1 mg/kg on days 0, 14, 28, 42, and 56. As maintenance, patients received oral cyclosporine (Neoral; Novartis) 10 mg/kg per day and mycophenolate mofetil (Myfenax; Teva, Petach Tikva, IL) 2000 mg/d from day 0. Cyclosporine was adjusted to achieve a trough level of 200 ng/mL during the first month and 150 to 100 ng/mL thereafter. From day 3, patients received oral prednisone 20 mg/d, tapered to 5 mg/d by month 1.

Favi E., Puliatti C., Iesari S., Monaco A., Ferraresso M, & Cacciola R. (2018). Impact of Donor Age on Clinical Outcomes of Primary Single Kidney Transplantation From Maastricht Category-III Donors After Circulatory Death. Transplantation Direct, 4(10), e396.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!